The collaboration will deliver drug-development candidates by combining Bend’s problem-solving and formulation or processing expertise for delivering poorly soluble compounds with Xcelience’s early-phase development activities.
The program will increase stage-specific expertise and expand operational capacity in a manner that provides immediate streamlined solutions to clients with tight timelines for producing clinical supplies.
Xcelience CEO and president Derek Hennecke said the collaboration reduces project timelines and transfer risk more than would be possible if the two steps occurred sequentially.
Bend Research CEO Rod Ray said the collaboration includes integration of Xcelience’s strengths in drug-product development and clinical-supply manufacturing with their company’s expertise in science- and engineering-based formulations for low-solubility compounds and our own drug-product intermediate clinical-supply manufacture.
”This will enable us to provide our high-quality, innovative solutions for clients in shorter timeframes, which can be critical in the development of new medicines," Ray said.